About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
The University of Kansas Cancer Center
https://www.kucancercenter.org/
2023 Multidisciplinary Oncology Review
2022
Advances in Hematologic Malignancies and Cellular Therapeutics Symposium
2022 Post San Antonio Review
Videos
2021
2021 Virtual KU Hematology and Medical Oncology Review
2021 Post San Antonio Review
2021 KUMC Virtual Multidisciplinary Oncology Review
2020
ASH Review VIRTUAL 2020: Current Updates in Hematologic Diseases
2020 ASCO Highlights
2019
2019 Post San Antonio Breast Cancer Review
ASH 2019 Review: Current Updates in Hematologic Diseases
2019 Lung Cancer and Head & Neck Cancer Symposium
Hematology & Medical Oncology Review 2019
Lung
Hematologic Malignancies
Gastrointestinal
Head and Neck
Genitourinary
Skin
Palliative
General
Event
2018
ASH: Current Updates in Hematologic Diseases
Events
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
K
1L Therapy for Ph- B-ALL: What Is Blinatumomab MRD Response & RFS? Is There Improved CR/CRI of Inotuzumab + Chemo?
By
ASH Review VIRTUAL 2020: Current Updates in Hematologic Diseases
FEATURING
Ken Byrd
By
ASH Review VIRTUAL 2020: Current Updates in Hematologic Diseases
FEATURING
Ken Byrd
11 views
March 5, 2021
0 Comments
Login to view comments.
Click here to Login
Featured Video
15:14
Icahn School of Medicine at Mount Sinai
Safety Profile of Ruxolitinib in Patients With MF
Feat.
D. Tremblay
Featured Video
13:04
Winship Cancer Institute - Emory University
Treatment-Related Quality of Life in MF
Feat.
A. Hunter
ASH Review VIRTUAL 2020: Current Updates in Hematologic Diseases
17:35
ASH Review VIRTUAL 2020: Current Updates in Hematologic Diseases
COVID-19 Coagulopathy: What Is Virchow’s Triad? What Are the VTE Rat…
Feat.
P. Harris
18:31
ASH Review VIRTUAL 2020: Current Updates in Hematologic Diseases
COVID-19 Therapeutics: Remdesivir/Bamlanivimab/Casirivimab+Imdevimab…
Feat.
K. Konrardy
15:40
ASH Review VIRTUAL 2020: Current Updates in Hematologic Diseases
COVID-19 & Hematologic Malignancies: What Is the Mortality Estim…
Feat.
J. Leal
19:48
ASH Review VIRTUAL 2020: Current Updates in Hematologic Diseases
2021 Updates on Thrombosis: VTE & Recurrence, Use of DOACs in GI…
Feat.
K. Halkidis
17:38
ASH Review VIRTUAL 2020: Current Updates in Hematologic Diseases
CAR-T & Experimental Therapeutics for AML: Is Allo-SCT the Only …
Feat.
T. Lin
15:46
ASH Review VIRTUAL 2020: Current Updates in Hematologic Diseases
SCT for MDS: Do Older Patients With Advanced MDS Benefit From Allo-H…
Feat.
A. Singh
05:21
ASH Review VIRTUAL 2020: Current Updates in Hematologic Diseases
HCT in MF: Is OS Better With Upfront JAKi vs. HCT? What Are the Outc…
Feat.
A. Singh
09:23
ASH Review VIRTUAL 2020: Current Updates in Hematologic Diseases
ASH Update on HCT for AML: Are We Starting to Refer AML Patients Ear…
Feat.
M. Mushtaq
07:01
ASH Review VIRTUAL 2020: Current Updates in Hematologic Diseases
Allogeneic Transplantation & AML Outcomes: What Is the Role of H…
Feat.
M. Mushtaq
08:38
ASH Review VIRTUAL 2020: Current Updates in Hematologic Diseases
ASH Update on Myelofibrosis: What Are the Outcomes After Ruxolitinib…
Feat.
A. Yacoub
07:44
ASH Review VIRTUAL 2020: Current Updates in Hematologic Diseases
ASH Update on CML Management: Does the TKI Choice Affect Survival? A…
Feat.
A. Yacoub
09:26
ASH Review VIRTUAL 2020: Current Updates in Hematologic Diseases
1L Therapy for Ph- B-ALL: What Is Blinatumomab MRD Response & RF…
Feat.
K. Byrd
09:20
ASH Review VIRTUAL 2020: Current Updates in Hematologic Diseases
1L Therapy for T-ALL: What Are the AALL0434 vs. AALL1231 EFS/OS Outc…
Feat.
K. Byrd
06:36
ASH Review VIRTUAL 2020: Current Updates in Hematologic Diseases
ASH Update on Intensive Induction for AML: What Is the 5-Year Follow…
Feat.
H. Male
11:45
ASH Review VIRTUAL 2020: Current Updates in Hematologic Diseases
ASH Update on Moderate-Intensity Chemo for AML: What Are the Remissi…
Feat.
H. Male
11:54
ASH Review VIRTUAL 2020: Current Updates in Hematologic Diseases
ASH Update on MDS Management: What Are the Outcomes of Venetoclax fo…
Feat.
B. Skikne
08:01
ASH Review VIRTUAL 2020: Current Updates in Hematologic Diseases
TP53 Mutations in MDS: Is Combination of Eprenetapopt + AZA Well-Tol…
Feat.
B. Skikne
14:31
ASH Review VIRTUAL 2020: Current Updates in Hematologic Diseases
ASH Update on Higher-Risk MDS: Efficacy/Safety of Pevonedistat + Aza…
Feat.
B. Skikne
